Drug Trial Radar · NCT06526624
A Study of HS-20093 vs Active Surveillance in Limited-Stage Small Cell Lung Cancer
Last checked: Nov 19, 2026Latest source record: Jul 30, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
406
Planned (sponsor's estimate)
Start
Sep 30, 2024
Primary completion
Nov 30, 2027
Study completion Jan 31, 2029
Sponsor
- Lead sponsor
- Hansoh BioMedical R&D CompanyIndustry
- Sponsor type
- Industry
- First posted
- Jul 30, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will evaluate the efficacy, safety and tolerability of HS-20093 compared with active surveillance as consolidation therapy after chemoradiotherapy in participants with limited-stage small cell lung cancer.
Conditions
- Limited-stage Small-cell Lung Cancer
Interventions
HS-20093Drug
Subjects in experimental arm will be given HS-20093 intravenously at a dose of 8.0 mg/kg every 3 weeks, until disease progression or until other criteria for treatment discontinuation are met.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-free survival (PFS) According to RECIST v1.1 by Independent Review Committee (IRC)Time frame: Approximately 6 years
- Overall survival (OS)Time frame: Approximately 6 years
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.